Abpro Corporation is a clinical-stage biotechnology company, that engages in developing next-generation antibody therapies, for patients with severe disease in multiple areas, including immuno-oncology/cancer, infectious disease, ophthalmology, and autoimmunity.
Its lead product candidates include ABP-100 for the treatment of breast, gastric, and endometrial cancers; ABP-201 for the treatment of vascular diseases of the eye;...
Abpro Corporation is a clinical-stage biotechnology company, that engages in developing next-generation antibody therapies, for patients with severe disease in multiple areas, including immuno-oncology/cancer, infectious disease, ophthalmology, and autoimmunity.
Its lead product candidates include ABP-100 for the treatment of breast, gastric, and endometrial cancers; ABP-201 for the treatment of vascular diseases of the eye; ABP-150 for gastric cancer; and ABP-300 for COVID-19. Abpro Corporation has partnership agreements with Essex Bio-Investment Ltd., AbMed Corporation, MedImmune Ltd., and Luye Pharma Group Ltd., Memorial Sloan Ketterin
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.